High-dose versus low-dose intravesical interferon-alpha 2b in the treatment of carcinoma in situ: a randomized, controlled study.
Eighty-seven patients with carcinoma in situ of the bladder were randomized to receive either 10 MU (low dose, 38 patients) or 100 MU (high dose, 47 patients) of recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year. The 100 MU dose produced a significantly greater incidence of complete responses than the 10 MU dose (43 and 5%, respectively), p less than 0.0001. Adverse effects of treatment were infrequent except for mild-to-moderate flu-like symptoms, which occurred in 8% and 17% of patients from the low- and high-dose groups, respectively.
Sarosdy
M
M
Division of Urology, University of Texas, San Antonio.
D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins